Printer Friendly

BIOPOOL FILES FOR FDA 510(k) PRE-MARKET NOTIFICATION APPROVAL FOR NEW PRODUCT LINE

 VENTURA, Calif., Nov. 3 /PRNewswire/ -- Biopool International Inc. (NASDAQ: BIPL) today announced that it has filed a submission with the Food and Drug Administration (FDA) through the 510(k) Premarket Notification process to market a new product line of controls used in drug abuse testing.
 Biopool's new products consist of seven different controls for a total of 10 drugs that are commonly used in pre-employment screening and random drug testing, as well as forensic crime laboratory testing.
 Drug abuse testing in the United States is estimated to include approximately 15 million people annually. The National Institute on Drug Abuse mandates that a minimum of 10 percent of the specimens tested for drugs of abuse in the United States include quality control samples, or one control sample for every nine specimens.
 "Our new controls function as performance checks on drug abuse tests currently used in clinical laboratories across the United States," said Michael D. Bick, Ph.D., chairman and chief executive officer. "The current market for these control products is estimated to be $30 million annually in the U.S. alone, representing approximately 50 percent of the worldwide market. The U.S. market will be the initial target market for these new products which we believe offer certain competitive advantages."
 Bick added that this 510(k) filing is significant since these new drug abuse control products represent a diversification of Biopool's product line beyond its current diagnostic tests used in hemostasis and fibrinolysis. "This move represents a continuation of our efforts to expand and enhance Biopool's product offering to address a broader range of product requirements in the clinical laboratory," Bick stated.
 Founded in 1987, Biopool develops, manufactures and markets a full range of test kits to assess and diagnose disorders of blood coagulation, fibrinolysis, platelet function, and the vascular system, as well as test kits to determine thrombotic risk factors. The company's products are sold to hospitals and clinical laboratories worldwide.
 -0- 11/3/93
 /CONTACT: Michael D. Bick, Ph.D., chairman and CEO, 805-654-0643; or Kim P. Feazle or Roger S. Pondel of Pondel Parsons & Wilkinson, 310-207-9300; or Andrew L. Cerskus, Ph.D., president and COO (Canada), 905-332-9419/
 (BIPL)


CO: Biopool International Inc. ST: California IN: MTC SU:

LM-MF -- LA006 -- 9986 11/03/93 09:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 3, 1993
Words:378
Previous Article:DELTA PETROLEUM ACQUIRES PROPERTIES IN PICEANCE BASIN
Next Article:THE CANTON INDUSTRIAL CORP. REVEALS NEW PLAN OF DIVERSIFICATION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters